Effects of survivin on FVADT chemotherapy for refractory multiple myeloma
| Autor: | Xingjun Du, Yuren Xi, Hua Yang |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Vincristine Pathology medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Immunology and Microbiology (miscellaneous) Internal medicine Survivin medicine Progression-free survival Dexamethasone Chemotherapy Hematology business.industry Articles General Medicine Fludarabine 030104 developmental biology 030220 oncology & carcinogenesis business medicine.drug Epirubicin |
| Zdroj: | Experimental and Therapeutic Medicine. 12:771-776 |
| ISSN: | 1792-1015 1792-0981 |
| DOI: | 10.3892/etm.2016.3401 |
| Popis: | The present study aimed to investigate the effects of survivin, an apoptosis inhibitor protein, on the efficacy of the fludarabine, vincristine, epirubicin, dexamethasone and thalidomide (FVADT) chemotherapy regime for the treatment of refractory multiple myeloma (MM). A total of 82 patients with MM were selected from the Hematology Inpatient Department at The Second Affiliated Hospital of Zhengzhou University (Zhengzhou, China). The initial treatment group consisted of 40 patients with MM, who received the vincristine, epirubicin and dexamethasone (VAD) chemotherapy regime. The refractory group consisted of 42 patients with refractory MM, who received the FVADT chemotherapy regime. Bone marrow biopsies were collected via marrow aspirations, and the protein expression of survivin was analyzed by immunohistochemistry. In addition, the Kaplan-Meier method was used for survival analyses. Intergroup differences in the protein expression levels of survivin were compared, and the association between survivin expression and the short- and long-term effects of FVADT chemotherapy were analyzed. The positive expression rate of survivin was significantly higher in the refractory group, as compared with the initial treatment group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|